Direct Implantation of Sirolimus-Eluting Stents With Bioresorbable Drug Carrier Technology Utilizing the Svelte Drug-Eluting Coronary Stent: The Direct III Post Market Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms Direct III
- Sponsors Svelte Medical Systems
- 12 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2016 Planned End Date changed from 1 Feb 2018 to 1 Sep 2018.
- 12 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2018.